TP53 and acute myeloid leukemia: Of these, eprenetapopt (APR-246), a first-in-class mutant p53 reactivator, has received considerable attention due to its early but compelling clinical efficacy when combined with azacitidine in TP53-mutant MDS and AML [43,44,45].